Scientists hope they’re closing in on a cure for COVID-19

June 1, 2021

While most of the world’s attention is currently laser focused on getting vaccines to more people to stem the spread of the coronavirus, there’s also significant pressure on scientists to find a cure.


In the Race for a Covid-19 Pill, a Little Lab Plays a Big Role

May 22, 2021

Nine years ago, Dr. Dennis Liotta, a professor of organic chemistry at Emory University, set out to change the way drugs are developed for so-called neglected diseases


Experimental drug from Emory could see immediate use in India COVID surge

April 27, 2021

Access to an experimental COVID-19 drug invented by Emory University researchers is being made immediately available to India as the country faces a new, catastrophic wave of infections.



Antios Therapeutics Raises $96 Million in a Series B Financing

April 12, 2021

Funding will support the Phase 2 clinical program of ATI-2173 in HBV

Soleus Capital led the round with new major investors RA Capital Management, Adage Capital Management LP, Pontifax and Aisling Capital as well as Altium Capital, Amzak Health, Granite Point Capital Management, LP, and LifeSci Venture Partners and participating existing investors Lumira Ventures, Cam Capital, Delos Capital, Domain Associates and Sixty Degree Capital


Antios Therapeutics Initiates First-in-Human Phase I Study of ATI-2173

Antios Therapeutics, Inc. (“Antios”), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat and cure viral diseases, today announced it has initiated its first-in-human Phase I clinical trial for ATI-2173, a novel liver-targeted, orally-administered, small molecule against hepatitis B.


Emory, collaborators testing antiviral drug as potential treatment for coronaviruses

February 3, 2020

An antiviral compound discovered at Emory University could potentially be used to treat the new coronavirus associated with the outbreak in China and spreading around the globe.